Результаты поиска - Richárd Márkus

  • Отображение 1 - 7 результаты of 7
Отмена результатов
  1. 1
    A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects

    A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects по Vladimir Hanes, Vincent Chow, Nan Zhang, Richárd Márkus

    Опубликовано 2017
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

    A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab по Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richárd Márkus

    Опубликовано 2016
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community

    Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community по Richárd Márkus, Jennifer Liu, Monica Ramchandani, Diana Landa, Teresa L. Born, Primal Kaur

    Опубликовано 2017
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  4. 4
    Estimation of Cachexia among Cancer Patients Based on Four Definitions

    Estimation of Cachexia among Cancer Patients Based on Four Definitions по Kathleen M. Fox, John M. Brooks, Shravanthi R. Gandra, Richárd Márkus, Chiun‐Fang Chiou

    Опубликовано 2009
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

    Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial по Gabriela Senti, Bettina M. Prinz Vavricka, Iris Erdmann, Mella I. Diaz, Richárd Márkus, Stephen J. McCormack, John Simard, Brunello Wüthrich, Reto Crameri, Nicole Graf, Pål Johansen, Thomas M. Kündig

    Опубликовано 2008
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis по Ronald L. Gibson, George Retsch‐Bogart, Christopher M. Oermann, Carlos Milla, Joseph M. Pilewski, Cori Daines, Richard C. Ahrens, Kevin León, Morty Cohen, Sharon McNamara, Tracy L. Callahan, Richárd Márkus, Jane L. Burns

    Опубликовано 2006
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

    NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives по Andrew D. Zelenetz, Islah Ahmed, Edward L. Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richárd Márkus, Ursula A. Matulonis, Denise K. Reinke, Edward C. Li, Jessica K. DeMartino, Jonathan K. Larsen, James M. Hoffman

    Опубликовано 2011
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: